Related Experiment Video
Updated: Jul 6, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
[New drugs; natalizumab]
H van Bronswijk1, E A Dubois, J M A van Gerven
1Leids Universitair Medisch Centrum, Albinusdreef 2, 2333 ZA Leiden.
Abstract:
The drug natalizumab represents a new pharmacological approach in the treatment ofvery active relapsing-remitting multiple sclerosis (MS). It is a humanised murine monoclonal antibody and binds to an integrin on the surface oflymphocytes, thereby preventing them from transmigrating across the endothelium and causing inflammation in the nervous tissue. The drug has been shown to decrease the occurrence of relapses and progression of MS. A few severe adverse effects (such as the viral progressive multifocal leuko-encephalopathy) have been reported, and its clinical and long-term effects are not fully known at present. Therefore, further research is required to determine the role of natalizumab in clinical practice.
More Related Videos
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
FDA Approved Drugs: Changes to Approved Drugs
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiepileptic Drugs: Glutamate Antagonists

